menu
    • menu

    Company profile for ReCode Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ReCode Therapeutics is a biopharmaceutical company developing precision medicines for genetic respiratory diseases with significant unmet medical need. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The Company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucle...
    ReCode Therapeutics is a biopharmaceutical company developing precision medicines for genetic respiratory diseases with significant unmet medical need. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The Company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ReCode TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Dallas/Fort Worth Metroplex, Southern US
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://recodetx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Recode Therapeutics Starts Enrollment of Phase 2 Trial Of RCT2100
    Recode Therapeutics Starts Enrollment of Phase 2 Trial Of RCT2100

    17 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251117123207/en/ReCode-Therapeutics-Initiates-Enrollment-of-Phase-2-Clinical-Trial-of-RCT2100-in-Combination-with-Ivacaftor-for-the-Treatment-of-Cystic-Fibrosis

    BUSINESSWIRE
    17 Nov 2025
    Share Share
    Recode Therapeutics Secures $29m For Genetic Medicines Pipeline
    Recode Therapeutics Secures $29m For Genetic Medicines Pipeline

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929553112/en/ReCode-Therapeutics-Announces-Over-%2429-Million-in-Additional-Financing-to-Advance-Genetic-Medicines-Pipeline-and-Provides-Corporate-Update

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    ReCode Therapeutics gets FDA Orphan Drug Designation for RCT2100
    ReCode Therapeutics gets FDA Orphan Drug Designation for RCT2100

    25 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250325006166/en/ReCode-Therapeutics-Receives-U.S.-FDA-Orphan-Drug-Designation-for-RCT2100-for-the-Treatment-of-Cystic-Fibrosis

    BUSINESSWIRE
    25 Mar 2025
    Share Share
    ReCode Receives Funding from CF Foundation for Gene Therapies
    ReCode Receives Funding from CF Foundation for Gene Therapies

    18 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241118891985/en

    BUSINESSWIRE
    18 Nov 2024
    Share Share
    ReCode Doses First Patient In CF Clinical Study
    ReCode Doses First Patient In CF Clinical Study

    26 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240926466940/en

    BUSINESSWIRE
    26 Sep 2024
    Share Share
    ReCode Therapeutics to Participate in Upcoming Investor Conferences
    ReCode Therapeutics to Participate in Upcoming Investor Conferences

    25 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240925745052/en

    BUSINESSWIRE
    25 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search